Empowering Pharmacists: South African Court Ruling Greenlights Pharmacist-Prescribed ARVs

By Staff Writer

August 16, 2023

In a landmark decision, the Pretoria High Court has given the South African Pharmacy Council (SAPC) the judicial green light to implement its Pharmacy-Initiated Management of Antiretroviral Treatment (PIMART) initiative. This allows specially trained pharmacists to manage and prescribe medicine to patients with HIV and tuberculosis.

Judge Elmarie van der Schyff dismissed an application by a doctors’ organisation, the IPA Foundation, to set aside the programme, stating the need for wider access to first-line ART and TPT therapy on a community level is a “dire need”.

The PIMART training course was created to qualify pharmacists in safely and effectively assisting in providing ART, upon successful completion.

This ruling is in line with the World Health Organization’s vision to promote widely accessible primary health care and recognizes the critical role pharmacies play in meeting healthcare needs, especially during pandemics like COVID-19.

Professor Francois Venter, former President of the Southern African HIV Clinicians Society and current Director of Ezintsha, an HIV research organisation, has emphasized the crucial role of pharmacies and pharmacists in expanding HIV services worldwide.

Let’s celebrate this win.

Reference url

Recent Posts

EU Life Sciences Strategy
         

EU Life Sciences Strategy: Paving the Way for Europe’s Leadership by 2030

🚀 Is Europe poised to reclaim its leadership in life sciences by 2030?

The European Commission has unveiled a game-changing strategy aimed at transforming the EU into the world’s leading hub for life sciences, tackling critical challenges in health, biotechnology, and sustainability. With strategic investments and reforms, this initiative promises to bridge the innovation gap and enhance public health outcomes across the continent.

Curious about how these plans will impact the life sciences landscape? Explore the full insights of this exciting strategy!

#SyenzaNews #HealthcareInnovation #DigitalTransformation #Innovation

ticagrelor data integrity
          

Ticagrelor Data Integrity Under Fire: Scrutiny Reveals Flaws in Key Clinical Trials

🔍 Are we truly getting the full story on high-cost medications like ticagrelor?

A recent BMJ investigation has raised alarm bells over the integrity of data from pivotal studies on AstraZeneca’s ticagrelor, revealing significant misreporting and missing data that may undermine its clinical benefits. This exposes critical implications for health economics, regulatory oversight, and market access.

Curious about how these findings could reshape perceptions of drug efficacy and safety? Dive into the full article to uncover the truth behind the numbers.

#SyenzaNews #HealthEconomics #Pharmaceuticals #MarketAccess

self-care public health
    

The Value of Self-Care in Public Health: Insights and Implications for Europe

🌍 Are we overlooking the power of self-care in Europe’s public health strategy?

The rise of self-care public health is reshaping how minor ailments are managed across the continent, leading to remarkable economic and productivity benefits. With annual savings of €36 billion and lifestyle improvements for consumers, self-care is proving to be a game-changer for healthcare systems.

Explore how embracing self-care can alleviate pressure on healthcare providers and enhance individual well-being. Dive into the full article to discover the implications for health economics and public policy!

#SyenzaNews #HealthEconomics #HealthcarePolicy

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.